MYXEDEMA COMA

Authors

  • Atif Munir University Hospital of Hartlepool

Abstract

Myxedema may be the first presentation of patients with undiagnosed hypothyroidism. Definitive management is with thyroid hormone but supportive measures, identification and treatment of precipitating factors in an appropriately safe environment are vital. There is no consensus about preferred thyroid hormone regimen. Corticosteroid therapy is given until adrenal insufficiency has been excluded. We present here a case of seventy-four years old woman of myxodema comaKeywords: Myxedema; hypothyroidism; precipitating factors; adrenal insufficiency

Author Biography

Atif Munir, University Hospital of Hartlepool

Department of Diabetes & EndocrinologySpecialty Registrar

References

Reinhardt W, Mann K. Incidence, clinical picture, and treatment of hypothyroid coma: results of a survey. Med Klin 1997;92(9):521–4.

Zwillich CW, Pierson DJ, Hofeldt FD, Lufkin EG, Weil JV. Ventilatory control in myxedema and hypothyroidism. N Engl J Med 1975;292(13):662–5.

Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990; 88(6):631–7.

MacKerrow SD, Osborn LA, Levy H, Eaton RP, Economou P. Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. Ann Intern Med 1992;117(12):1014–5.

Arlot S, Debussche X, Lalau JD, Mesmacque A, Tolani M, Quichaud J, et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. Intensive Care Med 1991;17(1):16–8.

Downloads

Published

2017-12-27

Most read articles by the same author(s)